molecular
farm
pharmaceut
plant
potenti
provid
almost
unlimit
amount
recombin
protein
use
diseas
diagnosi
prevent
treatment
tobacco
continu
major
crop
molecular
farm
offer
sever
practic
advantag
crop
produc
signific
leaf
biomass
high
solubl
protein
content
nonfood
crop
minim
risk
foodchain
contamin
combin
flexibl
highlyeffici
genet
transformationregener
made
tobacco
particularli
well
suit
plantbas
product
biopharmaceut
product
goal
review
provid
updat
use
tobacco
molecular
farm
biopharmaceut
well
technolog
develop
enhanc
protein
product
purificationefficaci
show
tobacco
robust
biolog
reactor
multitud
applic
may
hold
key
success
plant
molecular
farm
green
bioreactor
suffer
risk
pathogen
contamin
seen
mammalian
cell
cultur
known
crosskingdom
pathogen
plant
growth
requir
simpl
inexpens
compar
tradit
cell
cultur
system
allow
inexpens
nearli
unlimit
scalabl
case
plant
cell
cultur
use
much
simpl
growth
requir
mammalian
insect
cell
cultur
abl
util
light
main
energi
sourc
reduc
cost
addit
plant
system
robust
inert
allow
simplifi
handlingpurif
abil
case
pharmaceut
relev
protein
administ
oral
minim
process
establish
green
bioreactor
seemingli
mani
plant
speci
choos
advantag
disadvantag
depend
type
applic
desir
tobacco
nicotiana
tabacum
continu
major
platform
green
bioreactor
despit
tradit
neg
view
due
strong
tie
smoke
tobacco
offer
sever
uniqu
advantag
plant
speci
tobacco
often
refer
white
mous
plant
world
amic
genet
modif
becom
primari
vehicl
proofofconcept
work
recombin
protein
product
last
year
tobacco
leafi
plant
high
biomass
yield
leaf
biomass
per
hectar
high
solubl
protein
level
compar
mani
model
crop
speci
attract
featur
protein
product
platform
tobacco
also
offer
variou
way
express
protein
interest
transient
base
express
via
agrobacterium
viral
induct
stabl
nuclear
chloroplast
genom
base
express
avail
lownicotin
lowalkaloid
tobacco
varieti
cultivar
made
tobacco
plant
even
suitabl
direct
oral
deliveri
recombin
antigen
plant
materi
crude
protein
extract
menassa
et
al
tobacco
neither
food
feed
crop
thu
reduc
likelihood
transgen
materi
contamin
food
feed
chain
featur
made
tobacco
particularli
well
suit
plantbas
product
biopharmaceut
product
inde
number
therapeut
protein
produc
transgen
tobacco
plant
increas
steadili
sever
tobaccoderiv
product
advanc
human
clinic
trial
goal
review
discuss
applic
potenti
tobacco
green
bioreactor
recombin
therapeut
protein
product
tobacco
prove
attract
bioreactor
product
pharmaceut
relev
protein
addit
econom
advantag
tobacco
bioreactor
abil
produc
wide
rang
therapeut
protein
includ
antibodi
vaccin
immunomodulatori
molecul
cytokin
moreov
use
transient
protein
express
tobacco
abl
gener
signific
quantiti
protein
short
period
time
necessari
rapid
respons
diseas
outbreak
recent
influenza
pandem
patientspecif
treatment
cancer
antibodi
repres
singl
largest
class
new
drug
entiti
develop
time
gener
antibodi
pharmaceut
use
requir
coordin
creation
heavi
light
chain
correct
assembl
singl
function
unit
monoclon
antibodi
tradit
gener
use
hybridoma
cell
line
obtain
fusion
immort
cancer
cell
antibodyproduc
splenic
cell
isol
antigenchalleng
host
process
technic
challeng
growth
requir
maintain
hybridoma
cell
expens
bacteri
product
unfeas
due
inabl
glycosyl
assembl
function
antibodi
plant
offer
inexpens
altern
abl
produc
authent
antibodi
tobacco
first
host
chosen
express
function
recombin
fulllength
monoclon
antibodi
mab
antimous
catalyt
igg
plant
hiatt
et
al
shown
individu
tobacco
plant
express
singl
heavi
light
chain
gener
simpl
sexual
cross
two
parent
transgen
tobacco
line
result
progeni
line
express
accumul
fulli
assembl
function
mous
antibodi
high
level
total
solubl
protein
tsp
sinc
express
recombin
antibodi
use
tobacco
platform
extend
includ
monoclon
antibodi
complex
structur
secretori
iga
singlechain
antibodi
singlechain
antibodi
fragment
differ
specif
secretori
iga
siga
complex
multimer
protein
compos
two
iga
unit
heavi
light
chain
join
j
chain
secretori
compon
johansen
et
al
antibodi
natur
produc
bodi
protect
oral
mucos
surfac
infecti
organ
toxin
gener
uniqu
cooper
two
distinct
cell
type
j
chainexpress
plasma
cell
produc
polymer
p
iga
mainli
dimer
secretori
epitheli
cell
express
secretori
compon
sc
johansen
et
al
recombin
product
siga
mammalian
cell
difficult
expens
requir
two
independ
mix
cell
line
constant
monitor
cell
rebalanc
howev
tobacco
greatli
reduc
complex
recombin
product
best
exampl
tobaccobas
product
human
secretori
murin
guy
sigag
murin
monoclon
antibodi
guy
specif
recogn
saiii
protein
streptococcu
mutan
main
caus
agent
dental
cari
use
success
prevent
mutan
colon
develop
dental
cari
nonhuman
primat
well
human
clinic
trial
lehner
et
al
et
al
therefor
guy
igg
antibodi
potenti
treat
andor
prevent
dental
cari
produc
recombin
guy
sigag
transgen
tobacco
plant
gener
express
independ
either
guy
kappa
light
chain
hybrid
igag
antibodi
heavi
chain
murin
j
chain
rabbit
secretori
compon
sc
seri
sexual
cross
plant
research
produc
transgen
tobacco
plant
express
function
high
molecular
weight
secretori
murin
immunoglobulin
guy
sigag
accumul
level
per
gram
leaf
materi
et
al
human
clinic
trial
show
plantderiv
sigag
antibodi
prevent
oral
colonis
mutan
renam
tobaccoderiv
sigag
protein
becam
first
plantmad
antibodi
approv
human
use
european
union
tobacco
also
proven
effici
system
gener
fragment
antibodi
includ
singlechain
variabl
fragment
scfv
singlechain
antibodi
variabl
domain
fv
fragment
antibodybind
fab
fragment
see
tabl
small
recombin
synthet
antibodi
retain
full
antigenbind
activ
lack
specif
assembl
requir
use
diagnosi
treatment
souriau
hudson
express
level
scfv
deriv
tobacco
leav
vari
fecker
et
al
high
fiedler
et
al
tsp
moreov
multipl
sexual
cross
tobacco
line
express
individu
nonoverlap
scfv
transgen
tobacco
plant
express
one
nonoverlap
scfv
develop
provid
optim
protect
efficaci
multipl
infect
botulinum
neurotoxin
anthrax
simultan
almquist
et
al
risk
biolog
attack
sourc
inexpens
rapidli
produc
yet
effect
antibodi
utmost
import
vaccin
administr
antigen
materi
vaccin
produc
immun
diseas
vaccin
effect
costeffect
method
prevent
infecti
diseas
tradit
vaccin
administr
either
live
attenu
form
pathogen
bacteria
virus
kill
inactiv
form
pathogen
develop
subunit
vaccin
base
use
specif
protein
subunit
bacteri
pathogen
viru
less
risk
advers
reaction
whole
bacteri
viru
vaccin
use
recombin
dna
technolog
simplifi
product
subunit
vaccin
recombin
protein
subunit
vaccin
commonli
produc
e
coli
yeast
mammalian
cell
cultur
limit
scale
product
qualiti
product
cost
tobacco
emerg
promis
altern
express
system
product
recombin
subunit
vaccin
date
larg
number
vaccin
protein
produc
tobacco
plant
rang
vaccin
candid
foot
mouth
diseas
cholera
hepat
b
viru
sever
acut
respiratori
syndrom
sar
viru
human
immunodefici
viru
hiv
vaccin
candid
variou
cancer
see
tabl
mani
tobaccoderiv
vaccin
alreadi
proven
effect
anim
test
exampl
pogrebnyak
et
al
produc
sarscov
protein
tobacco
prevent
spread
highli
contagi
diseas
report
mice
prime
tobacco
made
protein
develop
immun
respons
produc
specif
igg
antibodi
anoth
exampl
golovkin
et
al
report
product
function
vaccinia
viru
protein
tobacco
potenti
vaccin
mice
immun
tobaccomad
protein
show
strong
immun
respons
suffici
protect
mice
lethal
dose
small
pox
tobacco
also
use
produc
vaccin
variou
veterinari
applic
dow
agrosci
receiv
approv
veterinari
use
newcastl
diseas
vaccin
poultri
first
tobacco
cellderiv
vaccin
approv
unit
state
depart
agricultur
vermij
waltz
increas
focu
tobacco
product
recent
year
led
clinic
evalu
recent
phase
clinic
trial
carri
patient
suffer
nonhodgkin
lymphoma
given
tobaccoderiv
person
patientspecif
idiotyp
singlechain
antibodi
scfv
vaccin
mccormick
et
al
idiotyp
singlechain
scfv
antibodi
deriv
patient
tumor
henc
allow
immun
patient
individu
therapeut
antigen
transient
tobaccovir
express
system
use
rapid
product
need
amount
idiotyp
vaccin
human
trial
result
demonstr
tobaccoderiv
idiotyp
vaccin
safe
administ
stimul
idiotypespecif
antibodi
cellular
immun
respons
cytokin
small
protein
glycoprotein
produc
varieti
cell
type
strong
immunoregul
modul
intens
durat
immun
respons
stimul
inhibit
activ
prolifer
andor
differenti
variou
cell
regul
secret
ab
cytokin
parkin
cohen
cytokin
exert
effect
bind
cytokin
receptor
express
membran
respons
target
cell
thomson
lotz
recombin
cytokin
wide
test
therapeut
agent
treatment
infecti
autoimmun
diseas
cancer
levi
niedbala
et
al
papaeti
et
al
weigert
et
al
although
mani
recombin
cytokin
commerci
avail
expens
use
therapeut
furthermor
lack
glycosyl
commerci
avail
recombin
cytokin
e
colideriv
glycosyl
import
protein
fold
stabil
function
recent
year
transgen
tobacco
exploit
new
sourc
inexpens
antilewi
mab
vitro
brodzik
et
al
cancer
broad
spectrum
mab
vitro
villani
et
al
cancer
colon
mab
anim
preclin
trial
ko
et
al
cancer
lee
et
al
foot
mouth
diseas
anim
preclin
trial
anim
preclin
trial
huang
et
al
helicobact
pylori
hspa
anim
preclin
trial
brodzik
et
al
ureb
vitro
gu
et
al
hepat
bc
hbsag
hep
b
anim
preclin
trial
thanavala
et
al
core
protein
hep
c
vitro
nianiou
et
al
hiv
hiv
capsid
protein
vitro
zhang
et
al
hivnef
vitro
marus
et
al
plagu
anim
preclin
trial
arlen
et
al
del
prete
et
al
sar
protein
anim
preclin
trial
pogrebnyak
et
al
tetanu
tetc
anim
preclin
trial
tregon
et
al
type
diabet
anim
preclin
trial
anim
preclin
trial
et
al
vitro
tremblay
et
al
insulin
anim
preclin
trial
li
et
al
ruhlman
et
al
type
diabet
vitro
brandsma
et
al
recombin
cytokin
function
express
human
gmcsf
human
murin
human
murin
viral
human
human
tobacco
plant
tobacco
cell
cultur
report
tabl
human
exampl
pleiotrop
regulatori
cytokin
potenti
treat
sever
human
diseas
includ
diabet
mellitu
thu
far
convent
express
system
recombin
human
product
proven
difficult
limit
effici
exampl
low
accumul
level
achiev
mutant
form
bear
amino
acid
substitut
express
e
coli
thompson
debinski
accumul
level
e
coli
could
improv
coexpress
fusion
maltos
bind
protein
contain
engin
tobacco
etch
viru
recognit
site
cterminu
tev
cleavag
prove
ineffici
requir
process
purifi
eisenmess
et
al
moreov
e
colideriv
unglycosyl
misfold
pack
inclus
bodi
addit
solubil
renatur
step
requir
biolog
activ
produc
thompson
debinski
make
use
e
coli
largescal
product
low
cost
unrealist
product
murin
nso
cell
also
ineffici
nso
cellderiv
exist
monomer
trimer
form
cannoncarlson
et
al
latter
form
biolog
activ
must
separ
biolog
activ
monomer
form
multistep
process
lower
product
effici
rais
cost
therefor
test
lownicotin
lowalkaloid
tobacco
cultivar
new
express
host
recombin
human
product
demonstr
human
protein
effici
accumul
transgen
tobacco
plant
present
multipl
molecular
form
express
level
high
tsp
leav
multipl
form
tobaccoderiv
recombin
due
differenti
nlink
glycosyl
reveal
enzymaticchem
deglycosyl
due
disulfidelink
oligomer
vitro
trypsin
digest
indic
plant
resist
proteolysi
unglycosyl
control
stabil
plant
digest
support
simul
gastric
intestin
fluid
digest
vitro
bioassay
use
factordepend
human
erythroleukem
cell
line
cell
show
plant
retain
biolog
function
authent
protein
result
suggest
transgen
plant
superior
convent
cellbas
express
system
product
oral
administr
protein
antigen
result
diminish
peripher
immun
respons
subsequ
system
challeng
antigen
process
known
oral
toler
weiner
well
establish
oral
toler
import
natur
physiolog
properti
immun
system
wherebi
host
avoid
danger
reaction
dth
delayedtyp
hypersensit
nondanger
antigen
substanc
encount
daili
diet
mowat
oral
toler
view
potenti
therapeut
strategi
prevent
treat
autoimmun
diseas
specif
diseaseinduc
self
antigen
autoantigen
glutam
acid
decarboxylas
gad
identifi
greater
patient
accept
oral
rather
system
therapi
eg
inject
antigen
specif
effect
without
toxic
effect
gener
immunosuppress
oral
toler
remain
attract
strategi
merit
clinic
test
oral
toler
shown
suppress
sever
autoimmun
diseas
anim
model
includ
experiment
allerg
encephalomyel
eae
uveiti
thyroid
myasthenia
arthriti
nonobes
diabet
nod
mous
well
inflammatori
condit
allergi
transplant
faria
weiner
oral
toler
induct
test
human
autoimmun
diseas
includ
multipl
sclerosi
ms
rheumatoid
arthriti
ra
uveiti
result
human
trial
suggest
system
toxic
exacerb
diseas
faria
weiner
induct
oral
toler
requir
repeat
administr
larg
dose
antigen
howev
clinic
applic
oral
toler
strategi
may
restrict
potenti
huge
cost
produc
autoantigen
new
express
platform
provid
larg
amount
function
protein
extrem
low
cost
highli
desir
make
oral
toler
effici
afford
therapeut
regimen
transgen
plant
express
system
potenti
produc
larg
amount
protein
econom
also
use
vehicl
direct
oral
deliveri
minim
process
peptid
protein
induc
oral
toler
group
explor
transgen
tobacco
plant
primari
vehicl
express
direct
oral
deliveri
autoantigen
gad
intend
induc
oral
toler
prevent
autoimmun
diabet
two
isom
gad
rodent
human
implic
mastel
blueston
rat
human
islet
express
predominantli
wherea
mous
islet
majorli
express
elliott
et
al
elliott
et
al
show
system
inject
young
nod
mice
specif
prevent
onset
diabet
provid
initi
proof
concept
use
transgen
plant
induc
oral
immun
toler
therefor
produc
transgen
tobacco
plant
express
mous
facilit
design
anim
experi
test
plantderiv
gad
et
al
show
first
time
feed
tobacco
plant
young
prediabet
femal
nod
prevent
develop
diabet
adjuv
facilit
toler
induct
reduc
dose
coadminist
autoantigen
interest
find
effect
mucos
adjuv
suitabl
longterm
administr
oral
toler
induct
use
transgen
plantbas
system
one
propos
mechan
oral
toler
associ
immun
deviat
caus
shift
immun
respons
proinflammatori
antiinflammatori
respons
cytokin
examin
possibl
enhanc
oral
toler
due
known
role
differenti
precursor
cell
lineag
mosmann
coffman
test
whether
cytokin
could
use
enhanc
oral
immun
toler
coadminist
autoantigen
gener
transgen
tobacco
plant
express
mous
human
tobaccoderiv
found
retain
biolog
activ
importantli
feed
nod
mice
tobacco
alon
effect
diabet
protect
combin
feed
tobacco
plant
protect
nod
mice
develop
diabet
recent
ruhlman
et
al
report
product
chloroplasttransform
lettuc
tobacco
plant
express
adjuv
antigen
consist
cholera
toxin
b
subunit
ctb
proinsulin
demonstr
oral
feed
transgen
plant
tissu
result
reduct
degre
insul
nod
mice
one
advantag
aspect
recombin
protein
product
tobacco
varieti
express
strategi
avail
strength
stabl
nuclear
transform
abl
meet
longterm
demand
authent
glycoprotein
antibodi
altern
chloroplastbas
express
provid
larg
quantiti
protein
requir
minim
posttransl
process
product
requir
rapid
turnaround
aforement
product
idiotyp
anticanc
vaccin
transient
express
would
expect
provid
use
amount
desir
protein
short
period
time
tobacco
offer
flexibl
meet
mani
differ
demand
potenti
excel
tobacco
nuclear
genom
readili
transform
via
agrobacterium
infect
biolist
deliveri
stabl
integr
nuclear
genom
allow
continu
recombin
protein
product
littl
extern
input
simultan
simplifi
product
reduc
cost
nuclear
express
protein
undergo
typic
eukaryot
posttransl
modif
store
varieti
organel
secret
depend
fuse
signal
peptid
major
concern
nuclear
base
express
howev
rel
lowlevel
accumul
recombin
protein
exist
number
option
address
issu
among
use
strong
constitutivetissu
specif
promot
enhanc
sequenc
increas
translat
effici
untransl
region
modif
increas
transcript
stabil
optim
code
sequenc
transgen
use
typic
tobacco
codon
streatfield
anoth
common
strategi
use
subcellular
local
signal
allow
sort
recombin
protein
specif
subcellular
locat
order
limit
proteolyt
degrad
henc
increas
accumul
benchaban
et
al
commonli
target
organel
increas
accumul
endoplasm
reticulum
er
via
attach
ctermin
kh
del
signal
deneck
et
al
follow
secret
golgi
apparatu
protein
return
er
low
level
proteolyt
activ
further
complex
molecular
fold
result
higher
level
accumul
mani
protein
recent
research
explor
local
recombin
protein
protein
bodi
protein
bodi
typic
form
storag
protein
found
seed
stabl
inert
compart
produc
bud
endoplasm
reticulum
highli
resist
proteolyt
degred
torrent
et
al
b
ad
protein
bodi
form
signal
peptid
refer
zein
desir
recombin
protein
express
retain
protein
bodi
allow
potenti
higher
level
accumul
one
studi
show
increas
accumul
fuse
recombin
protein
torrent
et
al
b
anoth
method
increas
recombin
protein
accumul
add
fusion
partner
increas
protein
stabilityproteolysi
resist
elastinlik
polypeptid
elp
one
exampl
elp
compos
pentapeptid
repeat
vpgxg
upon
addit
heat
andor
salt
undergo
revers
chang
conform
result
format
immisc
layer
water
allow
simplifi
downstream
purif
report
increas
accumul
level
fuse
protein
tobacco
patel
et
al
floss
et
al
inde
use
transient
express
system
fusion
elp
led
nearli
twice
level
gfp
accumul
er
due
abil
elp
induc
format
protein
bodi
cone
et
al
fusion
partner
increas
stabil
enhanc
immunogen
effect
tobacco
small
unstabl
antigen
peptid
desir
common
nontox
subunit
cholera
toxin
b
ctb
arakawa
et
al
ctb
enhanc
stabil
fuse
antigen
format
proteolyticresist
pentamer
structur
also
serv
effect
adjuv
enhanc
immunogen
fuse
protein
oral
deliveri
pentamer
structur
effici
bind
gangliosid
involv
antigen
display
holmgren
et
al
allow
product
unstabl
peptid
antigen
previous
unattain
tobacco
due
small
size
includ
bchain
insulin
fragment
daniel
et
al
b
li
et
al
tremblay
et
al
anoth
concern
tobacco
plant
gener
bioreactor
gener
therapeut
glycoprotein
tobacco
abl
creat
complex
glycoprotein
contain
plantspecif
glycan
main
complic
addit
residu
known
ige
bind
carbohydr
factor
plant
allergen
instanc
adventiti
especi
antibodi
intend
function
antigen
case
detriment
howev
result
either
glycoprotein
ineffectu
harm
host
seen
case
monoclon
murin
antibodi
lack
immunogen
due
nonauthent
glycosyl
chargelegu
et
al
number
approach
develop
produc
authent
glycoprotein
exampl
sever
group
achiev
success
knockdown
plant
transferas
activ
via
rnainterfer
rnai
result
shift
protein
glycosyl
away
planttyp
glycan
product
simpl
glycan
lack
ige
activ
sourrouil
et
al
strasser
et
al
anoth
approach
involv
express
human
abl
gener
monoclon
antibodi
nearli
ident
standard
made
hamster
cho
cell
bakker
et
al
fuse
human
galactosyltransferas
plant
ntermin
domain
abl
sequest
transferas
earli
golgi
apparatu
result
human
nglycan
ad
tobacco
nglycan
typic
ad
tobacco
cell
cultur
anoth
method
influenc
glycoprotein
composit
alter
makeup
growth
media
use
media
rich
glucosamin
research
abl
increas
ratio
simpl
complex
glycan
tobacco
cell
becerraarteaga
shuler
tobacco
chloroplast
offer
altern
stabl
express
system
nuclear
transform
shown
accumul
signific
level
recombin
protein
exampl
ruhlman
et
al
report
chloroplast
express
ctbinsulin
fusion
increas
accumul
similar
construct
nuclear
express
ruhlman
et
al
chloroplast
transform
refin
develop
highli
effici
recombin
protein
express
system
sinc
first
biolist
deliveri
recombin
dna
chloroplast
late
maliga
incorpor
chloroplast
genom
occur
homolog
recombin
typic
target
invert
repeat
region
reduc
extens
screen
requir
genom
transform
due
posit
effect
level
accumul
appear
vari
depend
express
cassett
use
type
protein
express
uncommon
see
level
express
rang
tsp
astound
amount
given
current
nuclear
transform
techniqu
typic
express
rang
tsp
daniel
et
al
b
grevich
daniel
recent
balli
et
al
perform
detail
analysi
recombin
protein
product
chloroplast
order
determin
plant
remain
metabol
healthi
despit
alter
resourc
caus
massiv
protein
accumul
found
rubisco
major
protein
plant
act
protein
sink
exist
natur
quantiti
greater
metabol
requir
recombin
protein
product
replac
rubisco
protein
sink
lead
lower
rubisco
level
rise
recombin
protein
accumul
allow
measur
natur
capac
recombin
protein
product
plant
without
affect
growth
develop
second
advantag
express
accumul
protein
tobacco
chloroplast
transgen
contain
plant
pollen
donat
dna
egg
cell
similar
embryo
fertil
human
human
organel
chloroplast
mitochondria
offspr
sole
matern
origin
therefor
gene
express
chloroplast
extens
plastid
highli
unlik
transmit
pollen
support
recent
work
demonstr
follow
fertil
pollen
contain
chloroplast
express
resist
marker
seedl
popul
million
progeni
show
patern
transmiss
ruf
et
al
therefor
combin
male
steril
line
tradit
leaf
specif
express
harvest
chloroplast
express
virtual
guarante
transgen
contain
tobacco
limit
chloroplast
recombin
protein
product
like
bacteria
unabl
perform
glycosyl
necess
mani
pharmaceut
glycoprotein
includ
monoclon
antibodi
import
note
howev
basic
build
block
glycan
present
within
chloroplast
fettk
et
al
thu
may
possibl
gener
glycoprotein
chloroplast
addit
multipl
step
glycan
additionmodif
pathway
although
yet
describ
literatur
transient
express
tobacco
allow
rapid
product
requir
protein
littl
day
post
infect
signific
quantiti
recombin
protein
gener
harvest
allow
rapid
turnaround
analysi
unachiev
via
stabl
genom
integr
mani
advanc
subcellular
local
fusion
describ
nuclear
transform
also
hold
true
transient
express
current
transient
express
system
use
tobacco
pharmaceut
product
use
viral
code
sequenc
deliv
agrobacterium
tumicfacien
provid
high
level
express
minim
input
order
maxim
effici
transient
express
variou
strategi
emerg
hold
potenti
drastic
increas
yield
one
promis
technolog
magnifect
design
minim
amount
wast
energi
use
creat
viral
particl
use
agrobacterium
deliv
deconstruct
viru
directli
cell
method
involv
deliveri
individu
compon
viral
express
platform
mix
differ
agrobacterium
line
harbour
fraction
viral
machineri
recombin
occur
intracellularli
infect
occur
alter
codon
usag
viru
inclus
typic
eukaryot
intron
abl
drastic
increas
effici
deliveri
result
reduct
amount
requir
infecti
agrobacterium
ie
l
overnight
cultur
could
use
infect
nearli
kg
tobacco
leaf
tissu
yield
kg
recombin
protein
tsp
marillonnet
et
al
exemplifi
measur
approach
current
explor
maxim
protein
yield
minim
input
cost
result
estim
raw
protein
purifi
addit
option
insert
viral
machineri
requir
inhibit
tobacco
silenc
via
stabl
nuclear
transform
first
minim
deliveri
requir
deconstruct
viral
vector
azhakanandam
et
al
two
major
drawback
transient
express
howev
first
technic
requir
induct
requir
mechan
deliveri
agrobacterium
plant
second
drawback
due
high
risk
unintend
spread
infect
wild
speci
necessit
work
must
confin
laboratori
greenhous
condit
although
less
concern
elimin
risk
crossfertil
normal
associ
openfield
grown
transgen
plant
gener
plant
pois
becom
new
rout
major
sourc
inexpens
pharmaceut
plantderiv
pharmaceut
need
meet
safeti
efficaci
standard
product
obtain
nonplant
sourc
mani
countri
process
creat
establish
guidelin
regulatori
polici
plantderiv
therapeut
us
plantmad
pharmaceut
research
develop
test
product
review
regul
us
depart
agricultur
usda
food
drug
administr
fda
usda
fda
regul
regard
develop
test
product
transport
commerci
plantmad
pharmaceut
expect
adapt
technolog
advanc
current
usda
field
permit
requir
plant
crop
produc
plantmad
pharmaceut
permit
grant
casebycas
basi
canada
experiment
field
test
biopharmaceut
crop
also
subject
govern
regul
requir
preapprov
permit
anticip
govern
approv
regul
plantmad
pharmaceut
may
strict
tradit
ethic
pharmaceut
plant
prove
effect
effici
bioreactor
product
pharmaceut
valuabl
recombin
protein
varieti
plant
speci
explor
serv
green
bioreactor
advantag
disadvantag
tobacco
offer
uniqu
blend
biomass
accumul
eas
manipul
protect
foodchain
contamin
biocontain
readili
found
plant
speci
technolog
develop
expans
rang
product
futur
oftmalign
plant
chanc
becom
posit
forc
improv
qualiti
life
